Doug covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies for GenomeWeb.
The grants are provided through the NSF's Early Concept Grants for Exploratory Research program in partnership with the National Institute of Food and Agriculture.
With the NIH grant funding, UCSD is establishing a new research center that will use systems biology to study antibiotic resistance in high-priority pathogens.
IQuity's current tests analyze gene expression patterns detected in mRNA, but the firm is also exploring the diagnostic potential of long non-coding RNAs.
In the effort, the researchers will analyze more than 2,000 placental and matched blood samples obtained from mothers and infants in two separate cohorts.
The technology is being used to analyze pathogen samples in a clinical study examining methods to combat recurrent drug-resistant Staph infections.
The company was spun out of the University of Florida to commercialize a technology to sequence genomes that have been simplified using PCR.
With the NIH funding, the researchers hope to gain new insights into the genetic causes of language impairment in various developmental and disease contexts.
The company is developing a proprietary circulating tumor cell identification and isolation technology that could be available for research use next year.
The company's technology is designed to enable PCR-free circulating cell-free DNA detection using either a luminometer or portable glucose meter.
The technology involves converting RNA-RNA interactions into unique DNA sequences, which are then analyzed using existing high-throughput sequencing platforms.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.